Breast cancer multigene germline panel testing in mainstream oncology based on clinical-public health utility (cancer mortality benefit): ESMO Precision Oncology Working Group recommendations
Clare Turnbull, Maria Isabel Achatz, Judith Balmañà, Elena Castro, Giuseppe Curigliano, Cezary Cybulski, Susan M. Domchek, D. Gareth Evans, Helen Hanson, N. Hoogerbrugge, Paul Andrew James, Amanda Krause, Katherine L. Nathanson, J. Ngeow Yuen Yie, Mark E. Robson, , William David Foulkes
The paper recommends a standardized multigene germline panel for breast cancer patients based on cancer mortality benefit, including specific genes and excluding others.
medRxiv · Feb 25, 2025 · PreprintGenetic & Genomic Medicine